An in vivo CRISPR approach has been performed in a transgenic murine model with Myc rearrangements, Eμ-myc, to identify and validate rare tumor suppressors such as Sp3 or Phip that could accelerate lymphomagenesis in the context of Myc translocation [110]. Here, MYC is linked to neoplasm.